We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Can Assess Risk of Type 2 Diabetes

By LabMedica International staff writers
Posted on 23 Feb 2024
Print article
Image: Jointly assessing biomarkers in a blood test could potentially predict type 2 diabetic risks (Photo courtesy of Edith Cowan University)
Image: Jointly assessing biomarkers in a blood test could potentially predict type 2 diabetic risks (Photo courtesy of Edith Cowan University)

The chronic and progressive nature of diabetes, along with its associated comorbidities, underscores the critical need for prompt action to tackle this significant health concern. Currently, the most widely utilized biomarker to forecast the risk of type 2 diabetes is high-sensitivity C-reactive protein (CRP). Recent studies, however, have indicated that assessing a combination of biomarkers, rather than evaluating each one separately, could enhance the ability to predict the risk of diabetes and its complications. Now, a new study has found that a blood test for jointly assessing biomarkers could potentially be used to predict a patient's risk of type 2 diabetes.

In the study, researchers from Edith Cowan University (Joondalup, Australia) examined the relationship between systemic inflammation, measured through a combined analysis of high-sensitivity CRP and another biomarker known as the monocyte to high-density lipoprotein ratio (MHR), and the onset of type 2 diabetes. This study tracked over 40,800 participants who did not have diabetes for nearly a decade, during which more than 4,800 participants developed the condition. Among those who developed type 2 diabetes, a significant interaction between MHR and CRP was noted. Specifically, as the MHR increased within each CRP category, so did the risk of developing type 2 diabetes; simultaneous increases in MHR and CRP were linked to significantly higher rates and risks of developing diabetes.

Moreover, the study revealed that the link between chronic inflammation (as indicated by the combined MHR and CRP levels) and new cases of diabetes was strongly dependent on age and sex and was affected by conditions such as hypertension, high cholesterol, or prediabetes. Adding MHR and CRP to the clinical risk model markedly enhanced the prediction of new diabetes cases. The study also found that women were at a higher risk of type 2 diabetes due to joint increases in CRP and MHR, with sex hormones playing a role in these differences. These findings supported the role of chronic inflammation in the early development of diabetes and underscored the need for targeted attention.

While age and genetics are factors that cannot be modified, other risk factors can be altered through changes in lifestyle. Inflammation is heavily influenced by lifestyle and metabolic conditions, including diet, sleep disturbances, chronic stress, and imbalances in glucose and cholesterol. This suggests the potential benefits of monitoring metabolic conditions related to risk. The cost-effectiveness and widespread availability of combined MHR and CRP testing in current clinical practice make these measures a promising and convenient tool for predicting diabetes risk.

"Epidemiological evidence indicates a consistent increase in early-onset diabetes, especially in developing countries,” said ECU researcher Dan Wu. “Leveraging this age-specific association between chronic inflammation and type 2 diabetes may be a promising method for achieving early identification of at-risk young adults and developing personalized interventions."

Related Links:
Edith Cowan University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.